TScan Therapeutics (TCRX) 24th Annual Needham Virtual Healthcare Conference summary

Company overview and technology

• Focuses on TCR-engineered T cell therapies for heme malignancies and solid tumors, with nine products in clinical development.

• Uses naturally occurring T cell receptors, not affinity-enhanced, to maximize safety and efficacy.

• Enhances TCR-T cells by introducing CD8 co-receptor and a dominant negative TGF-β receptor for solid tumors.

• Emphasizes leveraging natural immune processes and minimizing artificial modifications.

Clinical programs and trial updates

• Heme program targets AML, MDS, and ALL post-transplant, aiming to eliminate residual disease and prevent relapse.

• Phase I data show 8% relapse in treatment arm vs. 33% in control, aligning with historical relapse rates.

• Pivotal trial for TSC-101 planned for H2 2025, with top-line readout expected in H2 2027.

• TSC-102 series aims to expand addressable patient population by targeting additional HLA types.

Solid tumor strategy and multiplex therapy

• Solid tumor program addresses tumor heterogeneity by combining multiple TCRs per patient (multiplex therapy).

• Focus on PRAME and MAGE4 antigens, especially in lung, head and neck, and sarcomas.

• Plans to treat patients at effective dose levels and report first efficacy signals by end of year.

• Durability data for multiplex therapy expected to mature mid-to-late next year.